BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35655161)

  • 1. MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway.
    Su W; Feng B; Hu L; Guo X; Yu M
    BMC Cancer; 2022 Jun; 22(1):602. PubMed ID: 35655161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
    Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
    Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
    Yin F; Huang X; Xuan Y
    Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
    Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway.
    Li C; Zhan Y; Ma X; Fang H; Gai X
    Clin Exp Med; 2020 Feb; 20(1):79-86. PubMed ID: 31664539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
    Leiphrakpam PD; Are C
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyshikonin isolated from
    Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
    Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
    J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin14 promotes colorectal cancer progression via the PI3K/AKT/mTOR pathway.
    Qiao TY; Yuan ZM; Ma TY; Hu HQ; Zhu YH; Zhang WY; Zhang Q; Huang R; Tang QC; Wang GY; Wang XS
    Neoplasma; 2021 Sep; 68(5):947-954. PubMed ID: 34156255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
    Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUCKS1 promotes the progression of colorectal cancer via activating PI3K/AKT/mTOR signaling pathway.
    Zhu LL; Shi JJ; Guo YD; Yang C; Wang RL; Li SS; Gan DX; Ma PX; Li JQ; Su HC
    Neoplasma; 2023 Apr; 70(2):272-286. PubMed ID: 37226932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
    Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
    J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells.
    Li Q; Tang H; Hu F; Qin C
    J Cell Biochem; 2019 Mar; 120(3):3853-3860. PubMed ID: 30321450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression.
    Yang L; Dong Z; Li S; Chen T
    Aging (Albany NY); 2023 Mar; 15(8):2920-2936. PubMed ID: 37100467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis.
    Liu J
    Exp Cell Res; 2023 Sep; 430(1):113694. PubMed ID: 37391010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RFC2 promotes aerobic glycolysis and progression of colorectal cancer.
    Lou F; Zhang M
    BMC Gastroenterol; 2023 Oct; 23(1):353. PubMed ID: 37821801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.
    Zhong J; Ding S; Zhang X; Di W; Wang X; Zhang H; Chen Y; Zhang Y; Hu Y
    Front Biosci (Landmark Ed); 2023 Feb; 28(2):37. PubMed ID: 36866550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.